Z

ZYME

ZYME

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
50%Neutral
Buy/Sell Ratio89% buys
BearishBullish
ZYME Live QuoteReal-time
$26.14
$2.30(-8.09%)1M
Day Range$26.09 – $27.56
Open$26.30
Previous Close$26.86
Volume738.8K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$1.91B
P/E Ratio (TTM)51.4
Forward P/E42.4
EPS (TTM)$0.53
Price to Book7.0
Dividend Yield0.65%
Beta (Volatility)1.30
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $26.14 (44%)
Low: $21.52High: $31.97
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$43.29-71.1% upside

Insider Buys

14

$58.04M

Insider Sales

13

$7.40M

Total Volume

$65.44M

27 transactions

Net Activity

+$50.63M

Net buying

Proprietary Ratings
Calculated from Form 4 transactions
70CONFIDENCE

Sentiment Rating

Moderate Accumulation

CEO Conviction Index

Liquidating / Profit Taking

Key Drivers

  • •Strong buying bias: purchases represent 89% of total transaction value.
  • •CEO selling activity detected. Often driven by option expiration or diversification plans.
  • •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
E
1

Ecor1 Capital, LLC

Dir, 10%

14 buys0 sells

$58.04M total

G
2

Galbraith Kenneth

Chair, CEO

0 buys4 sells

$4.19M total

M
3

Moore Paul Andrew

Chief Scientific Officer

0 buys4 sells

$2.07M total

S
4

Smith Jeffrey T L

EVP, Chief Medical Officer

0 buys3 sells

$641K total

S
5

Schayowitz Adam

EVP, Head of R, D

0 buys1 sells

$358K total

Trading History
ZYME insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Nov 13, 2026

1 weeks ago

Moore Paul Andrew

Chief Scientific Officer

C-Level
Sell39.7K$26.07$1.04M

Oct 9, 2026

1 months ago

Schayowitz Adam

EVP, Head of R, D

EVP
Sell13.8K$25.85$358K

Jan 12, 2026

10 months ago

Hollywood Mark

EVP, COO

COO
Sell6.1K$22.67$139K

Jan 12, 2026

10 months ago

Smith Jeffrey T L

EVP, Chief Medical Officer

EVP
Sell9.3K$22.67$211K

Jan 12, 2026

10 months ago

Moore Paul Andrew

Chief Scientific Officer

C-Level
Sell9.6K$22.67$217K

Jan 12, 2026

10 months ago

Galbraith Kenneth

Chair, CEO

CEO
Sell30.4K$22.67$690K

Jan 5, 2026

10 months ago

Smith Jeffrey T L

EVP, Chief Medical Officer

EVP
Sell10.5K$25.10$264K

Jan 5, 2026

10 months ago

Galbraith Kenneth

Chair, CEO

CEO
Sell54.3K$25.10$1.36M

Jan 5, 2026

10 months ago

Moore Paul Andrew

Chief Scientific Officer

C-Level
Sell20.1K$25.10$505K

Dec 22, 2025

11 months ago

Galbraith Kenneth

Chair, CEO

CEO
Sell47.5K$27.02$1.28M

May 15, 2025

18 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy55.4K$11.47$636K

Apr 16, 2025

19 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy128.7K$11.32$1.46M

Apr 3, 2025

19 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy317.2K$11.42$3.62M

Mar 31, 2025

19 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy127.4K$11.75$1.50M

Mar 25, 2025

20 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy97.3K$12.61$1.23M

Mar 20, 2025

20 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy127.2K$12.92$1.64M

Mar 17, 2025

20 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy228.5K$12.55$2.87M

Mar 11, 2025

20 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy1.08M$12.13$13.12M

Jan 16, 2025

22 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy141.4K$13.88$1.96M

Jan 13, 2025

22 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy167.7K$13.59$2.28M

Jan 8, 2025

22 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy225.1K$13.21$2.97M

Jan 6, 2025

22 months ago

Moore Paul Andrew

Chief Scientific Officer

C-Level
Sell21.2K$14.92$316K

Jan 6, 2025

22 months ago

Galbraith Kenneth

Chair, CEO

CEO
Sell57.3K$14.92$855K

Jan 6, 2025

22 months ago

Smith Jeffrey T L

EVP, Chief Medical Officer

EVP
Sell11.1K$14.92$166K

Dec 30, 2024

23 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy363.4K$14.64$5.32M

Dec 24, 2024

23 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy130.3K$14.44$1.88M

Dec 19, 2024

23 months ago

Ecor1 Capital, LLC

Dir, 10%

Director
Buy1.25M$13.98$17.54M
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
ZYME Buy Conviction89%
Industry Rank#343 of 569
Volume Contribution0.4%
Total Industry Activity$16.52B

ZYME has an insider buy conviction of 89%, compared to the Unknown sector buy average of 6%. ZYME ranks #343 in insider activity out of 569 tracked companies in its industry.

Insider Trading Summary & Commentary
Automated executive transaction analysis for ZYME

Over the last 90 days, corporate insiders at ZYME (ZYME) engaged in a total of 27 transactions reported via SEC Form 4 filings. Among these, 14 were open-market purchases and 13 were sales. The total volume of insider trading reached $65.44M.

The net insider activity for ZYME shows a net buying bias of $50.63M. This activity represents a 89% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Purchase by Ecor1 Capital, LLC (Dir, 10%), who traded 1.25M shares valued at $17.54M on Dec 19, 2024.

Live Market News & Developments
Aggregated real-time headlines for ZYME (ZYME)
6 updates

Zymeworks Inc. (ZYME) Stock Price, News, Quote & History

Yahoo! Finance CanadaYesterday

Zymeworks Inc. (ZYME) stock price, news, quote and history

Yahoo Finance UKYesterday

Zymeworks management will join fireside chats at two Miami healthcare conferences.

Stock TitanYesterday

Zymeworks Authorizes Up to $200 Million in Share Repurchases Through 2028

TradingView4d ago

Zymeworks Chief Scientific Officer Andrew Paul Moore Sells $1M After Modest Run-Up

Benzinga4d ago

Zymeworks evp Scott Platshon sells $381,535 common stock By Investing.com

Investing.com South Africa2d ago

FAQs About ZYME Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for ZYME.

Based on SEC Form 4 disclosures, the Insider Confidence Score for ZYME is currently 70/100, which reflects a moderate accumulation bias. This calculation accounts for a total of 14 purchases and 13 sales by company executives over the last 90 days.

The CEO Conviction Index for ZYME is rated as "Liquidating / Profit Taking". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.